Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study

SIMPLE SUMMARY: The addition of bevacizumab or ramucirumab to systemic therapy for EGFR-mutated non-small-cell lung cancer (NSCLC) patients provides survival benefits. No study to date has compared the efficacy and safety of these two antiangiogenic therapies (AATs). This study enrolled patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wen-Chien, Shen, Yi-Cheng, Chen, Chieh-Lung, Liao, Wei-Chih, Chen, Chia-Hung, Chen, Hung-Jen, Tu, Chih-Yen, Hsia, Te-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913875/
https://www.ncbi.nlm.nih.gov/pubmed/36765600
http://dx.doi.org/10.3390/cancers15030642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913875/
https://www.ncbi.nlm.nih.gov/pubmed/36765600
http://dx.doi.org/10.3390/cancers15030642

Ejemplares similares